Cargando…

Simvastatin Enhances the Immune Response Against Mycobacterium tuberculosis

Tuberculosis remains a serious threat worldwide. For this reason, it is necessary to identify agents that shorten the duration of treatment, strengthen the host immune system, and/or decrease the damage caused by the infection. Statins are drugs that reduce plasma cholesterol levels and have immunom...

Descripción completa

Detalles Bibliográficos
Autores principales: Guerra-De-Blas, Paola Del Carmen, Bobadilla-Del-Valle, Miriam, Sada-Ovalle, Isabel, Estrada-García, Iris, Torres-González, Pedro, López-Saavedra, Alejandro, Guzmán-Beltrán, Silvia, Ponce-de-León, Alfredo, Sifuentes-Osornio, José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764081/
https://www.ncbi.nlm.nih.gov/pubmed/31616387
http://dx.doi.org/10.3389/fmicb.2019.02097
_version_ 1783454301683712000
author Guerra-De-Blas, Paola Del Carmen
Bobadilla-Del-Valle, Miriam
Sada-Ovalle, Isabel
Estrada-García, Iris
Torres-González, Pedro
López-Saavedra, Alejandro
Guzmán-Beltrán, Silvia
Ponce-de-León, Alfredo
Sifuentes-Osornio, José
author_facet Guerra-De-Blas, Paola Del Carmen
Bobadilla-Del-Valle, Miriam
Sada-Ovalle, Isabel
Estrada-García, Iris
Torres-González, Pedro
López-Saavedra, Alejandro
Guzmán-Beltrán, Silvia
Ponce-de-León, Alfredo
Sifuentes-Osornio, José
author_sort Guerra-De-Blas, Paola Del Carmen
collection PubMed
description Tuberculosis remains a serious threat worldwide. For this reason, it is necessary to identify agents that shorten the duration of treatment, strengthen the host immune system, and/or decrease the damage caused by the infection. Statins are drugs that reduce plasma cholesterol levels and have immunomodulatory, anti-inflammatory and antimicrobial effects. Although there is evidence that statins may contribute to the containment of Mycobacterium tuberculosis infection, their effects on peripheral blood mononuclear cells (PBMCs) involved in the immune response have not been previously described. Using PBMCs from 10 healthy subjects infected with M. tuberculosis H37Rv, we analyzed the effects of simvastatin on the treatment of the infections in an in vitro experimental model. Direct quantification of M. tuberculosis growth (in CFU/mL) was performed. Phenotypes and cell activation were assessed via multi-color flow cytometry. Culture supernatant cytokine levels were determined via cytokine bead arrays. The induction of apoptosis and autophagy was evaluated via flow cytometry and confocal microscopy. Simvastatin decreased the growth of M. tuberculosis in PBMCs, increased the proportion of NKT cells in culture, increased the expression of co-stimulatory molecules in monocytes, promoted the secretion of the cytokines IL-1β and IL-12p70, and activated apoptosis and autophagy in monocytes, resulting in a significant reduction in bacterial load. We also observed an increase in IL-10 production. We did not observe any direct antimycobacterial activity. This study provides new insight into the mechanism through which simvastatin reduces the mycobacterial load in infected PBMCs. These results demonstrate that simvastatin activates several immune mechanisms that favor the containment of M. tuberculosis infection, providing relevant evidence to consider statins as candidates for host-directed therapy. They also suggest that future studies are needed to define the roles of statin-induced anti-inflammatory mechanisms in tuberculosis treatment.
format Online
Article
Text
id pubmed-6764081
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-67640812019-10-15 Simvastatin Enhances the Immune Response Against Mycobacterium tuberculosis Guerra-De-Blas, Paola Del Carmen Bobadilla-Del-Valle, Miriam Sada-Ovalle, Isabel Estrada-García, Iris Torres-González, Pedro López-Saavedra, Alejandro Guzmán-Beltrán, Silvia Ponce-de-León, Alfredo Sifuentes-Osornio, José Front Microbiol Microbiology Tuberculosis remains a serious threat worldwide. For this reason, it is necessary to identify agents that shorten the duration of treatment, strengthen the host immune system, and/or decrease the damage caused by the infection. Statins are drugs that reduce plasma cholesterol levels and have immunomodulatory, anti-inflammatory and antimicrobial effects. Although there is evidence that statins may contribute to the containment of Mycobacterium tuberculosis infection, their effects on peripheral blood mononuclear cells (PBMCs) involved in the immune response have not been previously described. Using PBMCs from 10 healthy subjects infected with M. tuberculosis H37Rv, we analyzed the effects of simvastatin on the treatment of the infections in an in vitro experimental model. Direct quantification of M. tuberculosis growth (in CFU/mL) was performed. Phenotypes and cell activation were assessed via multi-color flow cytometry. Culture supernatant cytokine levels were determined via cytokine bead arrays. The induction of apoptosis and autophagy was evaluated via flow cytometry and confocal microscopy. Simvastatin decreased the growth of M. tuberculosis in PBMCs, increased the proportion of NKT cells in culture, increased the expression of co-stimulatory molecules in monocytes, promoted the secretion of the cytokines IL-1β and IL-12p70, and activated apoptosis and autophagy in monocytes, resulting in a significant reduction in bacterial load. We also observed an increase in IL-10 production. We did not observe any direct antimycobacterial activity. This study provides new insight into the mechanism through which simvastatin reduces the mycobacterial load in infected PBMCs. These results demonstrate that simvastatin activates several immune mechanisms that favor the containment of M. tuberculosis infection, providing relevant evidence to consider statins as candidates for host-directed therapy. They also suggest that future studies are needed to define the roles of statin-induced anti-inflammatory mechanisms in tuberculosis treatment. Frontiers Media S.A. 2019-09-20 /pmc/articles/PMC6764081/ /pubmed/31616387 http://dx.doi.org/10.3389/fmicb.2019.02097 Text en Copyright © 2019 Guerra-De-Blas, Bobadilla-Del-Valle, Sada-Ovalle, Estrada-García, Torres-González, López-Saavedra, Guzmán-Beltrán, Ponce-de-León and Sifuentes-Osornio. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Guerra-De-Blas, Paola Del Carmen
Bobadilla-Del-Valle, Miriam
Sada-Ovalle, Isabel
Estrada-García, Iris
Torres-González, Pedro
López-Saavedra, Alejandro
Guzmán-Beltrán, Silvia
Ponce-de-León, Alfredo
Sifuentes-Osornio, José
Simvastatin Enhances the Immune Response Against Mycobacterium tuberculosis
title Simvastatin Enhances the Immune Response Against Mycobacterium tuberculosis
title_full Simvastatin Enhances the Immune Response Against Mycobacterium tuberculosis
title_fullStr Simvastatin Enhances the Immune Response Against Mycobacterium tuberculosis
title_full_unstemmed Simvastatin Enhances the Immune Response Against Mycobacterium tuberculosis
title_short Simvastatin Enhances the Immune Response Against Mycobacterium tuberculosis
title_sort simvastatin enhances the immune response against mycobacterium tuberculosis
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764081/
https://www.ncbi.nlm.nih.gov/pubmed/31616387
http://dx.doi.org/10.3389/fmicb.2019.02097
work_keys_str_mv AT guerradeblaspaoladelcarmen simvastatinenhancestheimmuneresponseagainstmycobacteriumtuberculosis
AT bobadilladelvallemiriam simvastatinenhancestheimmuneresponseagainstmycobacteriumtuberculosis
AT sadaovalleisabel simvastatinenhancestheimmuneresponseagainstmycobacteriumtuberculosis
AT estradagarciairis simvastatinenhancestheimmuneresponseagainstmycobacteriumtuberculosis
AT torresgonzalezpedro simvastatinenhancestheimmuneresponseagainstmycobacteriumtuberculosis
AT lopezsaavedraalejandro simvastatinenhancestheimmuneresponseagainstmycobacteriumtuberculosis
AT guzmanbeltransilvia simvastatinenhancestheimmuneresponseagainstmycobacteriumtuberculosis
AT poncedeleonalfredo simvastatinenhancestheimmuneresponseagainstmycobacteriumtuberculosis
AT sifuentesosorniojose simvastatinenhancestheimmuneresponseagainstmycobacteriumtuberculosis